Details for Patent: 9,186,357
✉ Email this page to a colleague
Which drugs does patent 9,186,357 protect, and when does it expire?
Patent 9,186,357 protects AKYNZEO and is included in two NDAs.
This patent has sixty-eight patent family members in forty-one countries.
Summary for Patent: 9,186,357
| Title: | Compositions and methods for treating centrally mediated nausea and vomiting |
| Abstract: | Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery. |
| Inventor(s): | Trento; Fabio (Como, IT), Cantoreggi; Sergio (Cagiallo, CH), Rossi; Giorgia (Como, IT), Cannella; Roberta (Varese, IT), Bonadeo; Daniele (Varese, IT) |
| Assignee: | HELSINN HEALTHCARE SA (Lugano/Pazzallo, CH) |
| Application Number: | 14/069,927 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,186,357 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Dosage form; |
More… ↓ |
Drugs Protected by US Patent 9,186,357
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Helsinn Hlthcare | AKYNZEO | netupitant; palonosetron hydrochloride | CAPSULE;ORAL | 205718-001 | Oct 10, 2014 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY | ⤷ Subscribe | ||||
| Helsinn Hlthcare | AKYNZEO | fosnetupitant chloride hydrochloride; palonosetron hydrochloride | POWDER;INTRAVENOUS | 210493-001 | Apr 19, 2018 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY | ⤷ Subscribe | ||||
| Helsinn Hlthcare | AKYNZEO | fosnetupitant chloride hydrochloride; palonosetron hydrochloride | SOLUTION;INTRAVENOUS | 210493-002 | May 27, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,186,357
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 3083 | ⤷ Subscribe | |||
| Australia | 2010320598 | ⤷ Subscribe | |||
| Brazil | 112012011485 | ⤷ Subscribe | |||
| Canada | 2778301 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
